Claudia Cardone
About
Claudia Cardone is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Claudia Cardone has authored 42 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Claudia Cardone's work include Colorectal Cancer Treatments and Studies (28 papers), Lung Cancer Treatments and Mutations (15 papers) and Cancer Genomics and Diagnostics (10 papers). Claudia Cardone is often cited by papers focused on Colorectal Cancer Treatments and Studies (28 papers), Lung Cancer Treatments and Mutations (15 papers) and Cancer Genomics and Diagnostics (10 papers). Claudia Cardone collaborates with scholars based in Italy, Spain and Germany. Claudia Cardone's co-authors include Fortunato Ciardiello, Teresa Troiani, Giulia Martini, Davide Ciardiello, Pietro Paolo Vitiello, Erika Martinelli, Stefania Napolitano, Erika Martinelli, Nicola Normanno and Floriana Morgillo and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.
In The Last Decade
Claudia Cardone
42 papers receiving 1.0k citations
Peers
Claudia Cardone
Pietro Paolo Vitiello Italy
Ashiq Masood United States
Iosune Baraibar Spain
Marisol Huerta Spain
Gianluca Mauri Italy
Hao‐Xiang Wu China
Johannes Betge Germany
Takashi Kobunai Japan
Regula Deurloo Switzerland
Kalliopi Andrikou Italy
Citations per year, relative to Claudia Cardone Claudia Cardone (= 1×)
peers
Pietro Paolo Vitiello
Countries citing papers authored by Claudia Cardone
Since
Specialization
Citations
This map shows the geographic impact of Claudia Cardone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudia Cardone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudia Cardone more than expected).
Fields of papers citing papers by Claudia Cardone
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Claudia Cardone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudia Cardone. The network helps show where Claudia Cardone may publish in the future.
Co-authorship network of co-authors of Claudia Cardone
This figure shows the co-authorship network connecting the top 25 collaborators of Claudia Cardone. A scholar is included among the top collaborators of Claudia Cardone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claudia Cardone. Claudia Cardone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Stefano, Alfonso De, N. Zanaletti, Antonino Cassata, et al.. (2023). Heterogeneous disease and intermittent treatment in metastatic colorectal cancer: A case report. Frontiers in Oncology. 13. 1084681–1084681.
2.
Gyawali, Bishal, et al.. (2021). Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time. European Journal of Cancer. 150. 203–210.
3.
Vitiello, Pietro Paolo, Giulia Martini, Luigi Mele, et al.. (2021). Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. Journal of Experimental & Clinical Cancer Research. 40(1). 15–15.
4.
Martinelli, Erika, Davide Ciardiello, Giulia Martini, et al.. (2020). Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. Annals of Oncology. 31(1). 30–40.
5.
Martini, Giulia, Davide Ciardiello, Pietro Paolo Vitiello, et al.. (2020). Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?. Cancer Treatment Reviews. 86. 102023–102023.
6.
Falco, Vincenzo De, Pietro Paolo Vitiello, Emilio Francesco Giunta, et al.. (2019). Clinical practice use of liquid biopsy to identify RAS/BRAF mutational status in patients with metastatic colorectal cancer: A single institution experience. Annals of Oncology. 30. iv90–iv90.
7.
Cardone, Claudia, Erika Martinelli, Teresa Troiani, et al.. (2019). Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. ESMO Open. 4(4). e000519–e000519.
8.
Ciardiello, Davide, Pietro Paolo Vitiello, Claudia Cardone, et al.. (2019). Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. Cancer Treatment Reviews. 76. 22–32.
9.
Vitiello, Pietro Paolo, Claudia Cardone, Giulia Martini, et al.. (2019). Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. Journal of Experimental & Clinical Cancer Research. 38(1). 41–41.
10.
Corte, Carminia Maria Della, Vincenza Ciaramella, Claudia Cardone, et al.. (2018). Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. Journal of Thoracic Oncology. 13(6). 810–820.
11.
Vitiello, Pietro Paolo, Claudia Cardone, Davide Ciardiello, et al.. (2018). Receptor tyrosine kinase dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated colorectal cancer cell lines. Annals of Oncology. 29. viii1–viii1.
12.
Martinelli, Erika, Teresa Troiani, Vincenzo Sforza, et al.. (2018). Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. ESMO Open. 3(1). e000299–e000299.
13.
Sforza, Vincenzo, Erika Martinelli, Claudia Cardone, et al.. (2017). Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. ESMO Open. 2(4). e000229–e000229.
14.
Cardone, Claudia, Mariel C. Paul, Verónica Moreno‐Viedma, et al.. (2017). Eph A2 expression is a predictive biomarker of poorer activity and efficacy of FOLFIRI + cetuximab in RAS WT metastatic colorectal cancer (mCRC) patients (pts) in the CAPRI GOIM trial. Annals of Oncology. 28. v576–v576.
15.
Normanno, Nicola, Riziero Esposito Abate, Matilde Lambiase, et al.. (2017). RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. Annals of Oncology. 29(1). 112–118.
16.
Martini, Giulia, Teresa Troiani, Claudia Cardone, et al.. (2017). Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. World Journal of Gastroenterology. 23(26). 4675–4675.
17.
Sforza, Vincenzo, Erika Martinelli, Fortunato Ciardiello, et al.. (2016). Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World Journal of Gastroenterology. 22(28). 6345–6345.
18.
Martini, Giulia, Valentina Belli, Pietro Paolo Vitiello, et al.. (2016). blockade overcomes primary and acquired resistance to anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC). Annals of Oncology. 27. vi1–vi1.
19.
Maiello, Evaristo, Erika Martinelli, Claudia Cardone, et al.. (2016). Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by Next Generation Sequencing (NGS) in the CAPRI- GOIM trial. Annals of Oncology. 27. iv39–iv39.
20.
Cardone, Claudia, Giulia Martini, Teresa Troiani, et al.. (2015). Genetic Landscape of Primary Versus Metastatic Colorectal Cancer: to What Extent Are They Concordant?. Current Colorectal Cancer Reports. 11(5). 217–224.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Pietro Paolo Vitiello Breakdown of academic impact, for papers by Ashiq Masood Breakdown of academic impact, for papers by Iosune Baraibar Breakdown of academic impact, for papers by Marisol Huerta Breakdown of academic impact, for papers by Gianluca Mauri Breakdown of academic impact, for papers by Hao‐Xiang Wu Breakdown of academic impact, for papers by Johannes Betge Breakdown of academic impact, for papers by Takashi Kobunai Breakdown of academic impact, for papers by Regula Deurloo Breakdown of academic impact, for papers by Kalliopi Andrikou